Company Filing History:
Years Active: 2025
Title: The Innovative Contributions of Andrew Pickett
Introduction
Andrew Pickett is a notable inventor based in Uppsala, Sweden. He has made significant contributions to the field of neurotoxin formulations. His work focuses on creating stable liquid formulations that are free of animal proteins, which have important therapeutic applications.
Latest Patents
Andrew Pickett holds a patent for a liquid neurotoxin formulation stabilized with tryptophan or tyrosine. This invention relates to stable liquid neurotoxin formulations that include a surfactant, an amino acid selected from tryptophan and tyrosine, and a buffer comprising sodium, chloride, and phosphate ions. The formulations have a pH between 5.5 and 8 and are stable for two months. These compositions are suitable for therapeutic use, particularly for administration to patients to achieve desired therapeutic or aesthetic effects. The invention also highlights the use of tryptophan and tyrosine to protect proteinaceous neurotoxins from degradation in liquid compositions that are free of animal-derived proteins.
Career Highlights
Throughout his career, Andrew has worked with prominent companies in the pharmaceutical industry. He has been associated with Ipsen Biopharm Limited and Galderma Holding SA, where he contributed to the development of innovative therapeutic solutions.
Collaborations
Andrew has collaborated with notable colleagues, including Anders Jarstad and Anna Friis. Their combined expertise has furthered advancements in the field of neurotoxin formulations.
Conclusion
Andrew Pickett's innovative work in developing stable liquid neurotoxin formulations has significant implications for therapeutic applications. His contributions continue to influence the field and pave the way for future advancements.